Loading...
AMYT logo

Amryt Pharma plcNasdaqGS:AMYT Voorraadrapport

Marktkapitalisatie US$940.7m
Prijs aandeel
n/a
US$20.75
n.v.t.intrinsieke korting
1Y86.5%
7D0.7%
1D
Portefeuillewaarde
​
Bekijk

Amryt Pharma plc

NasdaqGS:AMYT Voorraadrapport

Marktkapitalisatie: US$940.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Amryt Pharma (AMYT) Aandelenoverzicht

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. Meer informatie

Beloningen

De winst zal naar verwachting met 53.88% per jaar groeien

De winst is de afgelopen 5 jaar met 34.4% per jaar gegroeid

Risicoanalyse

Geen risico's gedetecteerd voor AMYT uit onze risicocontroles.

AMYT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Amryt Pharma plc Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Amryt Pharma
Historische aandelenkoersen
Huidige aandelenkoersUS$14.70
52 Week HoogtepuntUS$14.77
52 Week LaagUS$6.41
Bèta0.75
1 maand verandering0.96%
3 maanden verandering-0.14%
1 Jaar Verandering86.55%
3 jaar veranderingn/a
5 jaar veranderingn/a
Verandering sinds IPO84.91%

Recent nieuws en updates

Seeking Alpha • Oct 18

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The EMA's Committee for Orphan Medicinal Products (COMP) adopted the positive opinion. "The COMP recommendation to maintain the orphan disease designation for Mycapssa confirms the significant benefit of Mycapssa over the currently available injectable forms of somatostatin analogues, which represents a significant development for acromegaly sufferers in Europe," said Amryt CEO Joe Wiley. In September, EMA's Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of Mycapssa as a maintenance therapy for certain patients with acromegaly. The orphan drug status in the EU provides for incentives, including 10 years' of market exclusivity for the drug, if approved.
Seeking Alpha • Sep 16

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's (NASDAQ:AMYT) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The decision of the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 3 trial called MPOWERED. The European Commission (EC), which generally follows the opinion of the CHMP, will now decide on the drug's approval. The EC decision is expected within within 67 days, the company said in a Sept. 16 press release. "The CHMP recommendation for approval of Mycapssa is a very significant development for acromegaly sufferers in Europe and Mycapssa would be the first and only oral somatostatin analog approved in the EU," said Amryt CEO Joe Wiley.
Seeking Alpha • Sep 08

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Irish commercial-stage biopharma Amryt (NASDAQ:AMYT) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarket trading. The UK's Medical Healthcare & Products Regulatory Agency granted a marketing authorization and an orphan drug designation to Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older, AMYT said in a statement. "We look forward to continuing our discussions with the reimbursement agencies across the UK and European Union to begin delivering Filsuvez to treat patients as soon as possible...," AMYT CEO Joe Wiley said. The nod from the British regulator comes after the European Commission approved Filsuvez in Aug. The U.S. FDA rejected the company's approval application for Filsuvez in Feb., with Amryt (AMYT) later saying it would appeal the so-called complete response letter.
Seeking Alpha • Jul 14

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.
Seeking Alpha • Jun 23

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

The European Commission (EC) approved Amryt's (NASDAQ:AMYT) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile and can tear or blister from minor injury/rubbing. Filsuvez will be the first and only approved therapy for patients EB, the Dublin-based company said in a June 23 press release. The approval was backed by data from a phase 3 trial called EASE which included 58 sites in 28 countries. The company noted that authorization of Filsuvez® in the EU provides a regulatory core dossier which may form the basis for future regulatory submissions in LATAM and the Middle East. A day ago, Krystal Biotech (KRYS) filed for U.S. approval of its topical gene therapy B-VEC to treat patients with dystrophic EB.

Recent updates

Seeking Alpha • Oct 18

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The EMA's Committee for Orphan Medicinal Products (COMP) adopted the positive opinion. "The COMP recommendation to maintain the orphan disease designation for Mycapssa confirms the significant benefit of Mycapssa over the currently available injectable forms of somatostatin analogues, which represents a significant development for acromegaly sufferers in Europe," said Amryt CEO Joe Wiley. In September, EMA's Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of Mycapssa as a maintenance therapy for certain patients with acromegaly. The orphan drug status in the EU provides for incentives, including 10 years' of market exclusivity for the drug, if approved.
Seeking Alpha • Sep 16

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's (NASDAQ:AMYT) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The decision of the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 3 trial called MPOWERED. The European Commission (EC), which generally follows the opinion of the CHMP, will now decide on the drug's approval. The EC decision is expected within within 67 days, the company said in a Sept. 16 press release. "The CHMP recommendation for approval of Mycapssa is a very significant development for acromegaly sufferers in Europe and Mycapssa would be the first and only oral somatostatin analog approved in the EU," said Amryt CEO Joe Wiley.
Seeking Alpha • Sep 08

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Irish commercial-stage biopharma Amryt (NASDAQ:AMYT) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarket trading. The UK's Medical Healthcare & Products Regulatory Agency granted a marketing authorization and an orphan drug designation to Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older, AMYT said in a statement. "We look forward to continuing our discussions with the reimbursement agencies across the UK and European Union to begin delivering Filsuvez to treat patients as soon as possible...," AMYT CEO Joe Wiley said. The nod from the British regulator comes after the European Commission approved Filsuvez in Aug. The U.S. FDA rejected the company's approval application for Filsuvez in Feb., with Amryt (AMYT) later saying it would appeal the so-called complete response letter.
Seeking Alpha • Jul 14

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.
Seeking Alpha • Jun 23

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

The European Commission (EC) approved Amryt's (NASDAQ:AMYT) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile and can tear or blister from minor injury/rubbing. Filsuvez will be the first and only approved therapy for patients EB, the Dublin-based company said in a June 23 press release. The approval was backed by data from a phase 3 trial called EASE which included 58 sites in 28 countries. The company noted that authorization of Filsuvez® in the EU provides a regulatory core dossier which may form the basis for future regulatory submissions in LATAM and the Middle East. A day ago, Krystal Biotech (KRYS) filed for U.S. approval of its topical gene therapy B-VEC to treat patients with dystrophic EB.
Seeking Alpha • Dec 09

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma is developing and delivering innovative medicines for rare and debilitating conditions. The Company has acquired three companies since formation, and has commercialized three medicines. The Company also has a significant development pipeline.

Rendement voor aandeelhouders

AMYTUS PharmaceuticalsUS Markt
7D0.7%2.6%2.5%
1Y86.5%41.5%26.4%

Rendement versus industrie: AMYT overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 41.5 % opleverde.

Rendement versus markt: AMYT overtrof de US markt, die het afgelopen jaar een rendement opleverde van 26.4 %.

Prijsvolatiliteit

Is AMYT's price volatile compared to industry and market?
AMYT volatility
AMYT Average Weekly Movement0.4%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stabiele aandelenkoers: De aandelenkoers van AMYT is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van AMYT is het afgelopen jaar gedaald van 16% naar 0%.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2015289Joe Wileywww.amrytpharma.com

Amryt Pharma plc Samenvatting

Hoe verhouden de winst en inkomsten van Amryt Pharma zich tot de beurswaarde?
AMYT fundamentele statistieken
MarktkapitalisatieUS$940.67m
Inkomsten(TTM)-US$790.00k
Inkomsten(TTM)US$243.62m
3.9x
P/S-verhouding
-1,191x
Koers/Winstverhouding

Is AMYT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AMYT resultatenrekening (TTM)
InkomstenUS$243.62m
Kosten van inkomstenUS$111.31m
BrutowinstUS$132.32m
Overige uitgavenUS$133.11m
Inkomsten-US$790.00k

Laatst gerapporteerde inkomsten

Sep 30, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-0.012
Brutomarge54.31%
Nettowinstmarge-0.32%
Schuld/Eigen Vermogen Verhouding64.3%

Hoe presteerde AMYT op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2023/04/14 09:59
Aandelenkoers aan het einde van de dag2023/04/11 00:00
Inkomsten2022/09/30
Jaarlijkse inkomsten2021/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Amryt Pharma plc wordt gevolgd door 8 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Michelle GilsonCanaccord Genuity
Brandon FolkesCantor Fitzgerald & Co.
Andrew YoungDavy